Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jan;35(1):51–54. doi: 10.1111/j.1365-2125.1993.tb05670.x

Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring.

R Fogari 1, E Malacco 1, F Tettamanti 1, A E Gnemmi 1, M Milani 1
PMCID: PMC1381490  PMID: 8448068

Abstract

A randomized, double-blind, placebo controlled study evaluated the effects on 24 h ambulatory blood pressure (ABP) of isradipine sustained release (I-SRO) administered once daily, in the morning (AM) or in the evening (PM). Eighteen uncomplicated essential hypertensives (10 men, mean age 55 +/- 6 years) with casual sitting DBP 96-110 mm Hg received, according to a triple-way crossover design, I-SRO 5 mg AM, or 5 mg PM, or placebo for 4 weeks. A 24 h ABP monitoring (Spacelabs 90207) was carried out at the end of each treatment. Twenty-four hour BP was 145.3/89.8 mm Hg after randomized placebo. AM and PM I-SRO significantly reduced 24 h BP, by 13.7/8.7 and 12.9/8.2 mm Hg respectively. Daytime (07.00 h-23.00 h) BP significantly decreased by 15.0/9.7 mm Hg with AM and 13.2/8.7 mm Hg with PM regimen; night-time BP (23.00 h-07.00 h) significantly decreased by 11.6/7.1 and 12.3/7.4 mm Hg, respectively. Nocturnal nadir BP values were 132.6/78.1 after randomized placebo, 120.9/71.4 after AM I-SRO and 121.0/72.4 mm Hg after PM I-SRO. Morning peak BP values were 154.6/96.9, 139.5/87.6 and 137.5/85.5 mm Hg, respectively. Mean BP values in the early morning hours (i.e. between 03.00 h and 08.00 h) were significantly decreased by 12.1/7.3 mm Hg after AM and 14.3/7.9 mm Hg after PM intake. No significant differences were detected in the BP lowering effect of the two I-SRO regimens.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreotti F., Davies G. J., Hackett D. R., Khan M. I., De Bart A. C., Aber V. R., Maseri A., Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol. 1988 Sep 15;62(9):635–637. doi: 10.1016/0002-9149(88)90669-8. [DOI] [PubMed] [Google Scholar]
  2. Casadei R., Parati G., Pomidossi G., Groppelli A., Trazzi S., Di Rienzo M., Mancia G. 24-hour blood pressure monitoring: evaluation of Spacelabs 5300 monitor by comparison with intra-arterial blood pressure recording in ambulant subjects. J Hypertens. 1988 Oct;6(10):797–803. [PubMed] [Google Scholar]
  3. Dahlöf B. Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension. Am J Med. 1989 Apr 17;86(4A):19–26. doi: 10.1016/0002-9343(89)90185-x. [DOI] [PubMed] [Google Scholar]
  4. Degaute J. P., van de Borne P., Linkowski P., Van Cauter E. Quantitative analysis of the 24-hour blood pressure and heart rate patterns in young men. Hypertension. 1991 Aug;18(2):199–210. doi: 10.1161/01.hyp.18.2.199. [DOI] [PubMed] [Google Scholar]
  5. Diemont W. L., Stegeman C. J., Beekman J., Siegers A. M., Hagels G., de Bruijn J. H. Low-dose isradipine once daily effectively controls 24-h blood pressure in essential hypertension. Am J Hypertens. 1991 Feb;4(2 Pt 2):163S–167S. doi: 10.1093/ajh/4.2.163s. [DOI] [PubMed] [Google Scholar]
  6. Fitscha P., Meisner W., Hitzenberger G. Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension. J Cardiovasc Pharmacol. 1991;18 (Suppl 3):S12–S14. [PubMed] [Google Scholar]
  7. Hof R. P., Hof A., Scholtysik G., Menninger K. Effects of the new calcium antagonist PN 200-110 on the myocardium and the regional peripheral circulation in anesthetized cats and dogs. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):407–416. doi: 10.1097/00005344-198405000-00006. [DOI] [PubMed] [Google Scholar]
  8. Lacourcière Y., Poirier L., Dion D., Provencher P. Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. Am J Cardiol. 1990 Feb 15;65(7):467–472. doi: 10.1016/0002-9149(90)90812-f. [DOI] [PubMed] [Google Scholar]
  9. Leary W. P., Reyes A. J., Maharaj B., van der Byl K. Time course of the blood pressure response to oral isradipine in uncomplicated mild-to-moderate essential hypertension. Am J Hypertens. 1991 Feb;4(2 Pt 2):147S–150S. doi: 10.1093/ajh/4.2.147s. [DOI] [PubMed] [Google Scholar]
  10. Man in't Veld A. J., Holmes D. G., Lasance A., de Zwart P. Isradipine twice daily lowers blood pressure over 24 H. Am J Hypertens. 1991 Feb;4(2 Pt 2):131S–134S. doi: 10.1093/ajh/4.2.131s. [DOI] [PubMed] [Google Scholar]
  11. Mancia G., Parati G., Albini F., Villani A. Circadian blood pressure variations and their impact on disease. J Cardiovasc Pharmacol. 1988;12 (Suppl 7):S11–S17. doi: 10.1097/00005344-198812007-00003. [DOI] [PubMed] [Google Scholar]
  12. Mazer N., Abisch E., Gfeller J. C., Laplanche R., Bauerfeind P., Cucala M., Lukachich M., Blum A. Intragastric behavior and absorption kinetics of a normal and "floating" modified-release capsule of isradipine under fasted and fed conditions. J Pharm Sci. 1988 Aug;77(8):647–657. doi: 10.1002/jps.2600770802. [DOI] [PubMed] [Google Scholar]
  13. Millar-Craig M. W., Bishop C. N., Raftery E. B. Circadian variation of blood-pressure. Lancet. 1978 Apr 15;1(8068):795–797. doi: 10.1016/s0140-6736(78)92998-7. [DOI] [PubMed] [Google Scholar]
  14. Mulcahy D., Keegan J., Cunningham D., Quyyumi A., Crean P., Park A., Wright C., Fox K. Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. Lancet. 1988 Oct 1;2(8614):755–759. doi: 10.1016/s0140-6736(88)92414-2. [DOI] [PubMed] [Google Scholar]
  15. Muller J. E., Stone P. H., Turi Z. G., Rutherford J. D., Czeisler C. A., Parker C., Poole W. K., Passamani E., Roberts R., Robertson T. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985 Nov 21;313(21):1315–1322. doi: 10.1056/NEJM198511213132103. [DOI] [PubMed] [Google Scholar]
  16. Panza J. A., Epstein S. E., Quyyumi A. A. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med. 1991 Oct 3;325(14):986–990. doi: 10.1056/NEJM199110033251402. [DOI] [PubMed] [Google Scholar]
  17. Tofler G. H., Brezinski D., Schafer A. I., Czeisler C. A., Rutherford J. D., Willich S. N., Gleason R. E., Williams G. H., Muller J. E. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987 Jun 11;316(24):1514–1518. doi: 10.1056/NEJM198706113162405. [DOI] [PubMed] [Google Scholar]
  18. Welzel D., Burger K. J. The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine. Drugs. 1990;40 (Suppl 2):60–64. doi: 10.2165/00003495-199000402-00015. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES